anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the US, patients receiving warfarin therapy are rarely allowed to engage in patient self-management (PSM) which is less burdensome, less expensive, and safer than standard clinician-directed warfarin management. National and international evidence-based guideline panels strongly recommend PSM over other warfarin management methods for appropriate patients because it improves INR control, cuts risk of thrombosis and death by half without increasing bleeding risk, and increases patient satisfaction and quality of life. The reasons behind PSM underutilization in US settings have not been systematically assessed and validated. We will address this knowledge gap and provide foundational information for increasing PSM utilization within the US healthcare system. Our Aim 1 will assess and validate barriers and facilitators to PSM and evaluate their applicability to the US healthcare system; Aim 2 will develop and test PSM implementation strategies in US ambulatory care sites using rapid-cycle research methodology; and Aim 3 will assess implementation (feasibility, fidelity, adoption), clinical (effectiveness, safety, equity, patient-centeredness), and end-user (satisfaction) outcomes. The long-term objective of our application is to improve the safety of ambulatory warfarin therapy through increasing the implementation of PSM. Our research proposal is guided by an implementation science logic model that incorporates well-known implementation science frameworks to support the specific aims. Qualitative data collection and analysis for Aim 1 will be organized using the Consolidated Framework for Implementation Research (CFIR) a determinant framework that identifies five domains influencing implementation: Intervention, Inner Setting, Outer Setting, Individuals, and the Implementation Process. Constructs within each domain provide guidance on factors to identify and measure as potential implementation barriers or facilitators. PSM implementation activities in Aim 2 will be guided by the Quality Implementation Framework (QIF), which identifies the critical implementation process steps and specific actions related to these steps that can be utilized to achieve quality PSM implementation. Implementation strategies will be supported by the rapid-cycle research framework developed by the AHRQ Practice Based Research Network. Implementation outcomes in Aim 3 will be structured using the well-known Reach, Efficacy, Adoption, Implementation, Maintenance (RE-AIM) framework. We will utilize a type III hybrid research design to test PSM implementation strategies while observing/gathering information on PSM-related clinical and economic outcomes.
Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days. Then, the early bactericidal activity will be measured and compared to the other arms.
OBJECTIVE: To establish a model that can predict the risk of requiring mechanical ventilation within 48 h after admission in patients with sepsis.
METHODS: Data for patients with sepsis admitted to Dongyang People's Hospital from October 2011 to October 2023 were collected and divided into a modeling group and a validation group. Independent risk factors in the modeling group were analyzed, and a corresponding predictive nomogram was established. The model was evaluated for discriminative power (the area under the curve of the receiver operating characteristic curve, AUC), calibration degree (Hosmer-Lemeshow test), and clinical benefit (decision curve analysis, DCA). Models based on the Sequential Organ Failure Assessment (SOFA) scores, the National Early Warning Score (NEWS) scores and multiple machine learning methods were also established.
RESULTS: The independent factors related to the risk of requiring mechanical ventilation in patients with sepsis within 48 h included lactic acid, pro-brain natriuretic peptide (PRO-BNP), and albumin levels, as well as prothrombin time, the presence of lung infection, and D-dimer levels. The AUC values of nomogram model in the modeling group and validation group were 0.820 and 0.837, respectively. The nomogram model had a good fit and clinical value. The AUC values of the models constructed using SOFA scores and NEWSs were significantly lower than those of the nomogram (P < 0.01). The AUC value of the integrated machine-learning model for the validation group was 0.849, comparable to that of the nomogram model (P = 0.791).
CONCLUSION: The established nomogram could effectively predict the risk of requiring mechanical ventilation within 48 h of admission by patients with sepsis. Thus, the model can be used for the treatment and management of sepsis.
ALKBH5 is a master regulator of N6-methyladenosine (m6A) modification, which plays a crucial role in many biological processes. Here, we show that ALKBH5 is required for breast tumor growth. Interestingly, PRMT6 directly methylates ALKBH5 at R283, which subsequently promotes breast tumor growth. Furthermore, arginine methylation of ALKBH5 by PRMT6 increases LDHA RNA stability via m6A demethylation, leading to increased aerobic glycolysis. Moreover, PRMT6-mediated ALKBH5 arginine methylation is confirmed in PRMT6-knockout mice. Collectively, these findings identify a PRMT6-ALKBH5-LDHA signaling axis as a novel target for the treatment of breast cancer.
PURPOSE: To determine whether the number of functional teeth, including the remaining natural teeth and prosthetically restored missing teeth, is associated with the dietary inflammatory index (DII), a quantitative measure of the inflammatory potential of the overall diet, in middle-aged and older Japanese adults.
METHODS: National survey data from a non-institutionalized Japanese population aged ≥45 years was analyzed. Multivariable linear regression analyses were performed to assess the association between the DII score, which was calculated based on dietary records, and the number of functional teeth, which was determined during dental examination. All regression analyses were stratified according to the age groups 45-64, 65-74, and ≥75 years. The association between functional tooth units (FTUs) and the DII was assessed using sensitivity analysis.
RESULTS: In total, 2407 individuals (1053 men and 1354 women; mean age = 66.7 years) were included. Multivariable analysis revealed that the number of functional teeth was significantly inversely associated with the DII score among participants aged ≥75 years (regression coefficient per increase of one in the number of functional teeth = -0.050; 95% confidence interval = -0.089 to -0.010). The number of functional teeth was not associated with the DII score in younger age categories (i.e., those aged 45-74 years). As in the primary analysis, the number of FTUs was significantly inversely associated with the DII score only in the group aged ≥75 years.
CONCLUSIONS: A greater number of functional teeth was associated with a lower DII (i.e., diet with greater anti-inflammatory potential) in Japanese adults aged ≥75 years.
<P>PROBLEM TO BE SOLVED: To prepare a cleansing sterilizing liquid efficiently producible without causing any waste, to provide a method and an apparatus for producing the same, to provide a cleansing sterilizing instrument therefor, and to provide a highly convenient moistening material for cleansing and sterilizing use.  <P>SOLUTION: The cleansing sterilizing instrument comprises an ion-eluting unit 5 and a spraying section 6. In this instrument, the ion-eluting unit 5 works as follows: Metal ions( e.g. silver ions ) are eluted from a metallic carrier( metallic electrode ) in a volatile sterilizing solvent( e.g. alcohol or a petroleum-based solvent ) fed from a solvent container 2 to form the cleansing sterilizing liquid comprising the sterilizing solvent and the metal ions. The spraying section works as follows: By spraying the cleansing sterilizing liquid on object(s) to be cleansed ( e.g. finger(s) ), the object(s) can be imparted with a future antibacterial effect owing to the metal ions. The moistening material( e.g. cotton ball, gauze ) impregnated with the cleansing sterilizing liquid is also provided. Owing to this moistening material, the antibacterial effect by the remaining metal ions can be afforded even if the above sterilizing solvent is volatilized.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The purpose of this study is to determine if an additional injection of local anesthetic immediately prior to removal of the local anesthetic infiltration catheter on postoperative day one is effective in increasing pain reduction, patient satisfaction or outcome measures following total knee replacement (TKR). It is hypothesized that an additional injection of 30ml of .5% bupivacaine solution immediately before infiltration catheter removal will provide pain reduction, patient satisfaction and outcome measures equal or superior to catheter removal with no additional injection. The target enrollment for this study is 50 participants, 25 in each of groups one and two.

Patients who are undergoing unilateral total knee replacement (TKR) at Brigham and Women's Faulkner Hospital and meet all eligibility criteria will be informed about the study and asked if they would like to participate. Upon agreement, patient's consent will be obtained and they will be randomly assigned to a treatment group. Patients in group one (treatment group) will receive a 30ml dose of 0.5% bupivacaine solution injected into the local anesthetic infiltration catheter immediately prior to its removal on postoperative day one. Patients in group two (control group) will receive no additional medication during local anesthetic infiltration catheter removal.

Members of both groups will be asked to complete Visual Analog Scale (VAS) pain and satisfaction surveys and also to track daily narcotic pain medication consumption during the first week postoperatively. Measures of swelling in the operative knee will be collected for members of both groups at the first routine postoperative appointment approximately one week after surgery. Swelling will be measured using a Perometer which calculates the total volume of the extremity in cubic centimeters (Pero-System, Wuppertal, Germany). Proprioception will be measured using a SD Balancer (Biodex Medical Systems, Shirley, NY) which calculates the the overall stability index (OSI) and compares it to age standardized data. Quadriceps strength using a handheld dynamometer. Outcome measures will be collected for members of both groups prior to surgery and at the second routine postoperative appointment between 6 weeks after surgery. Swelling will be also measured at the first post-operative visit 1 week after surgery. These data measures, as well as any complications will be recorded and used for analysis at the completion of the study.

The Principal Investigator (PI) will review all pain, satisfaction, narcotic usage and proprioception data on a weekly basis with the research assistant (RA) as it is collected. These checks will help to ensure validity and patient safety. Privacy and confidentially will be assured by using codes as deidentifiers in place of identifying information on any data sheets used in analysis. Data which identifies the patient will be made available only to investigators and stored only in a private folder on department computers protected with a firewall. No data will be shared outside of Partners. Adverse events will be promptly reported to the PHRC as per PHRC rules.
Untreated patients with TFH-derived peripheral T-cell lymphoma will be treated with chidamide combined with azacitidine for four cycles. For patients with interim-PET evaluation of CR, consolidation therapy with ASCT or another eight cycles with chidamide combined with azacitidine can be obtained. Subsequently, cidarbenamide monotherapy was given as maintenance therapy for 12 months. Patients with interim evaluation of SD or PD withdrew from this study.
BACKGROUND: Stereotaxic Radiosurgery (SRS) is a non-invasive lesioning technique for movement disorders when patients cannot undergo DBS due to medical comorbidities.
OBJECTIVE: To describe and summarize the literature on SRS's application and physical parameters for Parkinson's disease (PD) motor symptoms.
METHODS: The MEDLINE/PUBMED and EMBASE databases were searched in July 2022 following the PRISMA guideline. Two independent reviewers screened data from 425 articles. The level of evidence followed the Oxford Centre for Evidence-Based Medicine. Pertinent details for each study regarding participants, physical parameters, and results were extracted.
RESULTS: Twelve studies reported that 454 PD patients underwent Gamma KnifeⓇ (GK). The mean improvement time of the treated symptoms was three months after GK. Tremor is the most common symptom investigated, with success rates ranging from 47.5% to 93.9%. Few studies were conducted for caudatotomy (GKC) and pallidotomy (GKP), which presented an improvement for dyskinesia and bradykinesia. Physical parameters were similar with doses ranging from 110 to 200 Gy, use of a 4-mm collimator with an advanced imaging locator system, and coordinates were obtained from available stereotactic atlases.
CONCLUSIONS: GK thalamotomy is a good alternative for treating tremor; however, its effects are delayed, and there are cases in which it can regress after years. The outcomes of GKC and GKP seem to be promising. The existing studies are more limited, and effects need to be better investigated.
The multivariate temporal response function (mTRF) is an effective tool for investigating the neural encoding of acoustic and complex linguistic features in natural continuous speech. In this study, we investigated how neural representations of speech features derived from natural stimuli are related to early signs of cognitive decline in older adults, taking into account the effects of hearing. Participants without ( n = 25  ) and with ( n = 19  ) early signs of cognitive decline listened to an audiobook while their electroencephalography responses were recorded. Using the mTRF framework, we modeled the relationship between speech input and neural response via different acoustic, segmented and linguistic encoding models and examined the response functions in terms of encoding accuracy, signal power, peak amplitudes and latencies. Our results showed no significant effect of cognitive decline or hearing ability on the neural encoding of acoustic and linguistic speech features. However, we found a significant interaction between hearing ability and the word-level segmentation model, suggesting that hearing impairment specifically affects encoding accuracy for this model, while other features were not affected by hearing ability. These results suggest that while speech processing markers remain unaffected by cognitive decline and hearing loss per se, neural encoding of word-level segmented speech features in older adults is affected by hearing loss but not by cognitive decline. This study emphasises the effectiveness of mTRF analysis in studying the neural encoding of speech and argues for an extension of research to investigate its clinical impact on hearing loss and cognition.
A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin β-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein. Furthermore, a protective effect of a glycosylated side chain CTP can lower the protease sensitivity of the linker peptide, making a linker region of the fusion protein less degradable.
It is intended to provide an LLPL gene and a novel use of its gene product. According to a screening method with the use of LLPL, preventives and/or remedies for various diseases caused by deficiency of LLPL can be efficiently screened. A nonhuman animal with hypoexpression of LLPL lacks various biological activities which would be induced by LLPL. Thus, it is usable as a model of various diseases induced by deficiency of LLPL. Therefore, the animal is useful in screening preventives and/or remedies for various symptoms caused by deficiency of LLPL (for example, diseases caused by apoptosis), clarifying causes of LLPL-associated diseases and discussing therapies therefor. Moreover, compounds which can be obtained by the above-described screening method are useful as preventives and/or remedies for diseases caused by apoptosis.
The present invention relates to gene engineering product field, more specifically, the invention discloses a kind of monoclonal antibody against EGFR with high-affinity and preparing the purposes in antitumor drug with it; Does is wherein the aminoacid sequence of variable region of heavy chain (VH) SEQ? IDNO:14, does is the aminoacid sequence of variable region of light chain (VL) SEQ? ID? NO:6 or SEQ? ID? the antibody of NO:12 compares raising at least 10 times with the avidity of EGFR with Cetuximab.
A recombinant non-human animal having an inactivated lats gene is described. A  lats knock-out mouse is exemplified. Because mice disrupted for the lats gene develop a variety of tumors, are susceptible to induction of skin tumors by exposure to carcinogens, and exhibit pituitary dysfunction, they have utility in screening for compounds effective to treat or prevent cancer or pituitary disorders. Compounds can be screened for activity in treating or preventing skin cancer in recombinant non-human animals which have an inactivated and in which skin tumors have been induced by exposure to carcinogens. Methods for treatment of cancers refractory to treatment with chemotherapy or radiation therapy by using a therapeutic that promotes lats function are also described.  Additional methods are described for the treatment or prevention of diseases and disorders associated with aberrant levels of cdc2 activity with a therapeutic that either promotes, inhibits or antagonizes lats function.
VAX128-01 is a first in human study of three inactivated recombinant novel H1N1 influenza vaccines, designated VAX128 A, B and C. The purpose of the study is to compare the safety and immunogenicity of the three vaccines through a range of doses and to select one of the vaccines for further testing in phase II studies. We plan to assess the safety and immunogenicity in a dose escalating study. The study will enroll up to 100 healthy young adults (18-49 years) and 100 healthy adults than age 65 years. We are including the older adults in this phase 1 study because we have found that the elderly tolerated a vaccine similar to one of the candidates, VAX128A, better than young adults, but required a higher vaccine dose to achieve a similar antibody response. Nevertheless, because we are testing two other constructs (VAX128B and C), we will be making the conservative assumptions that the safety and immunogenicity data coming from the young adults will not predict the results in the elderly. Therefore, we will begin the study in the young adults and after the first three dose levels have been tested we will begin testing in the older adults. In this study we plan to enroll up to 100 young adults and up to 100 adults 65 years and older. The young adults will be most likely enrolled at one clinical site and the older adults will be enrolled at another clinical site. We plan to enroll a cohort of 10 young adults and 10 older adults every week. Each cohort will consist of 3 subjects to receive one of the three vaccines (9 subjects total) and one subject in each cohort will receive placebo. Dosing for the next cohort will be based on a two day assessment period after vaccination. The main part of the study will be conducted over 28 days and there will be two follow up phone calls at 6 months and one year.
H\&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.
In this phase we aim to explore the views of the current decision-making process in thyroid cancer treatment. The patients will be approached for interview within 14 days after their consultations where the treatment decisions for their low risk differentiated thyroid cancer are made. There is no time restriction to approach clinicians for interview.
PURPOSE:To prepare an active fraction for lowering cholesterol level, useful as an orally administrable non-toxic antiarteriosclerotic agent and its raw material, by disintegrating the cultured cells of bacteria belonging to Streptococcus genus, treating the disintegrated cells with a proteinase, and removing a component having specific molecular weight from the product. CONSTITUTION:Bacterial strain belonging to Streptococcus genus (e.g. Streptococcus faecium, Streptococcus faecalis, etc.) is cultured by conventional method, and the bacterial cells are collected from the cultured product. The cells are disintegrated, and treated with a proteinase. The obtained suspension is dialyzed with a dialyzing membrane having a cut-off molecular weight of 3,500 (Cellotube; Nakarai chemical Co.) to remove the components having molecular weight of <=3,500 and obtain the active component for lowering cholesterol level. The extract fraction of bacterial cell derived from enteric bacteria is non-toxic by oral administration, and effectively lowers the cholesterol level in blood. It is effective to arteriosclerosis, hyperlipemia, hypertension, etc.
Initial chronic obstructive lung disease (COPD) pharmacotherapy is based on symptom burden and exacerbation history. Inclusion of inhaled cortico-steroids (ICS) is recommended only for those with a history of exacerbations. This brief report highlights that among individuals with previously unrecognized COPD about 1 in 5 have one or more exacerbation-like events and about 1 in 10 have two or more events in the prior 12 months whether or not they self-report concomitant asthma. Closer attention to prior exacerbation-like event history might lead to more guideline concordant care. In addition, there are two other groups that have impaired but non-obstructive spirometry, some with significant respiratory symptom burden who have frequencies of exacerbation-like events similar to those meeting COPD spirometry criteria. To date we have little guidance for treatment of these individuals.
Disclosed is a panty liner for women which improves sexual desires of women. The panty liner comprises a skin contact layer and an inner layer. The skin contact layer and the inner layer are two layers formed of medical non-woven fabrics, and a medicine bag is placed between the skin contact layer and the inner layer. The medicine bag is manufactured by using hydrosol to attach a powder in a traditional Chinese medicine volatile oil bag and by compressing the same. The traditional Chinese medicine volatile oil bag comprises 2-5 parts by weight of traditional Chinese medicine volatile oil compositions and 5-25 parts by weight of starch, and contains Fructus galangae oil, Fennel oil, Fructus evodiae oil and Fructus caryophylli oil, which are a traditional Chinese medicine volatile oil, as an effective amount. The pantyliner disclosed in the present invention is able to meaningfully improve sexual desires of women.